Loading
GRID showed that regorafenib held back GIST that had already escaped both imatinib and sunitinib, and gave patients a third line of targeted treatment.
GRID randomised 199 patients with metastatic or unresectable gastrointestinal stromal tumour that had progressed on imatinib and sunitinib two to one to regorafenib, a multikinase inhibitor of KIT, PDGFRA and VEGF receptors, or placebo, with crossover at progression. The primary endpoint was progression-free survival.
Regorafenib lengthened progression-free survival several-fold compared with placebo, with disease control in most patients, at the cost of hand-foot skin reaction, hypertension and diarrhoea. Overall survival was confounded by crossover. Regorafenib was approved in the United States in February 2013 as third-line therapy for GIST and held that place until ripretinib arrived in 2020.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
199 enrolled.
| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Progression-free survival (independent blinded central review)primary | Regorafenib | 133 | 4.8 months | 0.27 (0.19 to 0.39) | <0.0001 | link |
| Placebo | 66 | 0.9 months |
Shares Bayer, Regorafenib, Anti-angiogenic therapy, Sarcomas (soft tissue, bone, GIST) and the tag subtype-trials.
Shares Gastrointestinal stromal tumour (GIST), Sarcomas (soft tissue, bone, GIST), Small-molecule kinase inhibitors and the tag subtype-trials.
Shares Anti-angiogenic therapy, Sarcomas (soft tissue, bone, GIST), Small-molecule kinase inhibitors and the tag subtype-trials.
Shares Anti-angiogenic therapy, Small-molecule kinase inhibitors and the tag subtype-trials.
Shares Anti-angiogenic therapy, Small-molecule kinase inhibitors and the tag subtype-trials.
Shares Anti-angiogenic therapy, Small-molecule kinase inhibitors and the tag subtype-trials.
Shares Bayer and the tag subtype-trials.
Shares Bayer and the tag subtype-trials.